Abstract

For some decades, an increase in propagation of coronary heart disease, obesity, diabetes, tumors and mental disorders has been observed. Consequently, new and effective methods of treatment of these diseases using drugs and diet supplements have been developed. A promising solution is the use of polyunsaturated fatty acids in the treatment of some diseases.These compounds have broad application in prevention of many diseases and are used to support standard therapies. Their activity is connected with participation in metabolic processes regulating biochemical transformations in cells and tissues.Omega-3 fatty acids regulate production of cytokines, increased levels of which may contribute to occurrence of chronic inflammatory diseases, autoaggression of the immunological system, arteriosclerosis or tumor development. These substances exert a beneficial effect on the blood system by improvement of blood circulation and nerve signal transmission. Omega-3 fatty acids reduce the risk of irregular heartbeat, stabilize arterial pressure, and restore balance in cholesterol metabolism disorders.They also play a key role in maintaining physical and mental efficiency; thus administration of these compounds for young children is of great importance. Nevertheless, administration of omega-3 fatty acids in the diet seems to be essential. The purpose of this study is to present the structure and sources of omega-3 and – 6 fatty acids and discuss the problems concerning therapeutic use of these compounds in various disorders.

References

• 1. Adkins Y., Kelley D.S.: Mechanisms underlying the cardioprotectiveeffects of omega-3 polyunsaturated fatty acids. J. Nutr. Biochem.,2010; 21: 781-792
  Google Scholar
• 2. Ahima R.S., Antwi D.A.: Brain regulation of appetite and satiety.Endocrinol. Metab. Clin. North Am., 2008; 37: 811-823
  Google Scholar
• 3. Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I.,Donato K.A., Fruchart J.C., James W.P., Loria C.M., Smith S.C.Jr.: Harmonizingthe metabolic syndrome: a joint interim statement of theInternational Diabetes Federation Task Force on Epidemiology andPrevention; National Heart, Lung, and Blood Institute; AmericanHeart Association; World Heart Federation; International AtherosclerosisSociety; and International Association for the Study ofObesity. Circulation, 2009; 120: 1640-1645
  Google Scholar
• 4. Apte S.A., Cavazos D.A., Whelan K.A., Degraffenried L.A.: A lowdietary ratio of omega-6 to omega-3 fatty acids may delay progressionof prostate cancer. Nutr. Cancer, 2013; 65: 556-562
  Google Scholar
• 5. Artmann A., Petersen G., Hellgren L.I., Boberg J., Skonberg C., NellemannC., Hansen S.H., Hansen H.S.: Influence of dietary fatty acidson endocannabinoid and N-acylethanolamine levels in rat brain,liver and small intestine. Biochim. Biophys. Acta, 2008; 1781: 200-212 6 Balbás G.M., Regana M.S., Millet P.U.: Study on the use of omega-3fatty acids as a therapeutic supplement in treatment of psoriasis.Clin. Cosmet. Investig. Dermatol., 2011; 4: 73-77
  Google Scholar
• 6. fatty acids and 5-HTTLPR? J. Affect. Disorders, 2012; 136: 604-611
  Google Scholar
• 7. Baza leków. Kwasy tłuszczowe omega-3 (opis profesjonalny).http://bazalekow.mp.pl/leki/doctor_subst.html?id=2449(23.01.1015)
  Google Scholar
• 8. Beblo S., Reinhardt H., Demmelmair H., Muntau A.C., Koletzko B.:Effect of fish oil supplementation on fatty acid status, coordination,and fine motor skills in children with phenylketonuria. J. Pediatr.,2007; 150: 479-484
  Google Scholar
• 9. Brasky T.M., Darke A.K., Song X., Tangen C.M., Goodman P.J.,Thompson I.M., Meyskens F.L.Jr., Goodman G.E., Minasian L.M.,Parnes H.L., Klein E.A., Kristal A.R.: Plasma phospholipid fatty acidsand prostate cancer risk in the SELECT trial. J. Natl. Cancer Inst.,2013; 105: 1132-1141
  Google Scholar
• 10. Broncel M.: Blaski i cienie stosowania wielonienasyconych kwasówtłuszczowych omega-3 w chorobie niedokrwiennej serca – wynikibadania ALPHA OMEGA. Kardiol. Op. Fakt., 2010; 4: 326-332
  Google Scholar
• 11. Cabo J., Alonso R., Mata P.: Omega-3 fatty acids and blood pressure.Br. J. Nutr., 2012; 107 (Suppl. 2): 195-200
  Google Scholar
• 12. Calder P.C.: N-3 polyunsaturated fatty acids and inflammation:from molecular biology to the clinic. Lipids, 2003; 38: 343-352
  Google Scholar
• 13. Carroll D.N., Roth M.T.: Evidence for the cardioprotective effectsof omega-3 fatty acids. Ann. Pharmacother., 2002; 36: 1950-1956
  Google Scholar
• 14. Chamras H., Ardashian A., Heber D., Glaspy J.A.: Fatty acid modulationof MCF-7 human breast cancer cell proliferation, apoptosisand differentiation. J. Nutr. Biochem. 2002; 13: 711-716
  Google Scholar
• 15. Cicero A.F., Ertek S., Borghi C.: Omega-3 polyunsaturated fattyacids: their potential role in blood pressure prevention and management.Curr. Vasc. Pharmacol., 2009; 7: 330-337
  Google Scholar
• 16. Cichosz G., Czeczot H.: Stabilność oksydacyjna tłuszczów jadalnych– konsekwencje zdrowotne, Bromat. Chem. Toksykol., 2011; 44: 50-60
  Google Scholar
• 17. Czysz A.H., Rasenick M.M.: G-protein signaling, lipid rafts andthe possible sites of action for the antidepressant effects of N-3polyunsaturated fatty acids. CNS & Neurol. Disord. Drug Targets,2013; 12: 466-473
  Google Scholar
• 18. Davis T.A., Gao L., Yin H., Morrow J.D., Porter N.A.: In vivo andin vitro lipid peroxidation of arachidonate esters: the effect of fishoil ω-3 lipids on product distribution. J. Am. Chem. Soc., 2006; 128:14897-14904
  Google Scholar
• 19. Dawczynski C., Hackermeier U., Viehweger M., Stange R., SpringerM., Jahreis G.: Incorporation of n-3 PUFA and γ-linolenic acid inblood lipids and red blood cell lipids together with their influenceon disease activity in patients with chronic inflammatory arthritis– a randomized controlled human intervention trial. Lipids HealthDis., 2011; 10: 130
  Google Scholar
• 20. de Lorgeril M., Salen P., Defaye P., Rabaeus M.: Recent findingson the health effects of omega-3 fatty acids and statins, and theirinteractions: do statins inhibit omega-3? BMC Med., 2013; 11: 5
  Google Scholar
• 21. Deckelbaum R.J., Worgall T.S., Seo T.: n-3 fatty acids and geneexpression. Am. J. Clin. Nutr. 2006; 83: S1520-S1525
  Google Scholar
• 22. Derosa G., Maffioli P., D‘Angelo A., Salvadeo S.A., Ferrari I., FogariE., Gravina A., Mereu R., Randazzo S., Cicero A.F.: Effects of longchain ω-3 fatty acids on metalloproteinases and their inhibitorsin combined dyslipidemia patients. Expert Opin. Pharmacother.,2009; 10: 1239-1247
  Google Scholar
• 23. D‘Vaz N., Meldrum S.J., Dunstan J.A., Martino D., McCarthy S.,Metcalfe J., Tulic M.K., Mori T.A., Prescott S.L.: Postnatal fish oilsupplementation in high-risk infants to prevent allergy: randomizedcontrolled trial. Pediatrics, 2012; 130: 674-682
  Google Scholar
• 24. Dzielska-Olczak M., Nowak J.Z.: Leczenie przeciwzapalne w chorobiezwyrodnieniowej stawów z uwzględnieniem kwasów tłuszczowychomega 3 i omega 6. Pol. Merkur. Lekarski, 2012; 32: 329-334
  Google Scholar
• 25. Fetterman J.W.Jr., Zdanowicz M.M.: Therapeutic potential of n-3polyunsaturated fatty acids in disease. Am. J. Health Syst. Pharm.,2009; 66: 1169-1179
  Google Scholar
• 26. Flachs P., Rossmeisl M., Bryhn M., Kopecky J.: Cellular and moleculareffects of n-3 polyunsaturated fatty acids on adipose tissuebiology and metabolism. Clin. Sci., 2009, 116: 1-16
  Google Scholar
• 27. Furuhjelm C., Warstedt K., Fageras M., Falth-Magnusson K., LarssonJ., Fredriksson M., Duchen K.: Allergic disease in infants up to 2years of age in relation to plasma omega-3 fatty acids and maternalfish oil supplementation in pregnancy and lactation. Pediatr. AllergyImmunol., 2011; 22: 505-514
  Google Scholar
• 28. Garg M.L., Wood L.G., Singh H., Moughan P.J.: Means of deliveringrecommended levels of long chain n-3 polyunsaturated fattyacids in human diets. J. Food Sci., 2006; 71: R66-R71
  Google Scholar
• 29. Gheita T., Kamel S., Helmy N., El-Laithy N., Monir A.: Omega-3fatty acids in juvenile idiopathic arthritis: effect on cytokines (IL-1and TNF-α), disease activity and response criteria. Clin. Rheumatol.,2012; 31: 363-366
  Google Scholar
• 30. Gleissman H., Johnsen J.I., Kogner P.: Omega-3 fatty acids incancer, the protectors of good and the killers of evil? Exp. Cell Res.,2010; 316: 1365-1373
  Google Scholar
• 31. Golub N, Geba D., Mousa S.A., Williams G., Block R.C.: Greasingthe wheels of managing overweight and obesity with omega-3 fattyacids. Med. Hypotheses, 2011; 77: 1114-1120
  Google Scholar
• 32. Greenberg A.S., Obin M.S.: Obesity and the role of adipose tissuein inflammation and metabolism. Am. J. Clin. Nutr., 2006; 83:461S-465S
  Google Scholar
• 33. Helland I.B., Smith L., Blomén B., Saarem K., Saugstad O.D.,Drevon C.A.: Effect of supplementing pregnant and lactating motherswith n-3 very-long-chain fatty acids on children‘s IQ and body massindex at 7 years of age. Pediatrics, 2008; 122: e472-e479
  Google Scholar
• 34. Hibbeln J.R., Gow R.V.: The potential for military diets to reducedepression, suicide, and impulsive aggression: a review of currentevidence for omega-3 and omega-6 fatty acids. Mil. Med., 2014; 179(Suppl.): 117-128
  Google Scholar
• 35. Holm T., Andreassen A.K., Aukrust P., Andersen K., Geiran O.R.,Kjekshus J., Simonsen S., Gullestad L.: Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensiveheart transplant recipients. Eur. Heart J., 2001; 22: 428-436
  Google Scholar
• 36. Huffman S.L., Harika R.K., Eilander A., Osendarp S.J.: Essentialfats: how do they affect growth and development of infants andyoung children in developing countries? A literature review. Matern.Child Nutr., 2011; 7 (Suppl. 3): 44-65
  Google Scholar
• 37. Imhoff-Kunsch B., Stein A.D., Martorell R., Parra-Cabrera S.,Romieu I., Ramakrishnan U.: Prenatal docosahexaenoic acid supplementationanf infant morbidity: randomized controlled trial. Pediatrics,2011; 128: e505-e512
  Google Scholar
• 38. Innis S.M., Friesen R.W.: Essential n-3 fatty acids in pregnantwomen and early visual acuity maturation in term infants. Am. J.Clin. Nutr., 2008; 87: 548-557
  Google Scholar
• 39. Jabłońska-Trypuć A., Czerpak R.: Metabolizm nienasyconychkwasów tłuszczowych i ich znaczenie w profilaktyce i terapii układukrwionośnego. Prz. Kardiodiabetol., 2009; 4: 55-63
  Google Scholar
• 40. Kabir M., Skurnik G., Naour N., Pechtner V., Meugnier E., RomeS., Quignard-Boulangé A., Vidal H., Slama G., Clément K., Guerre–Millo M., Rizkalla S.W.: Treatment for 2 mo with n 3 polyunsaturatedfatty acids reduces adiposity and some atherogenic factors butdoes not improve insulin sensitivity in women with type 2 diabetes:a randomized controlled study. Am. J. Clin. Nutr., 2007; 86: 1670-1679
  Google Scholar
• 41. Kaviani M., Saniee L., Azima S., Sharif F., Sayadi M.: The effect ofomega-3 fatty acid supplementation on maternal depression duringpregnancy: a double blind randomized controlled clinical trial. Int.J. Community Based Nurs. Midwifery, 2014; 2: 142-147
  Google Scholar
• 42. Knefel K., Hese R.T.: Kwasy omega-3 a zaburzenia depresyjne,lękowe i schizofrenia. Psychiatr. Prakt. Klin., 2009; 2: 140-145
  Google Scholar
• 43. Kokoszka A.: Szansa na poprawę skuteczności leczenia schizofreniii depresji? Przegląd wyników badań suplementacji omega-3 wielonienasyconymikwasami tłuszczowymi. Przew. Lek., 2007; 10: 20-26
  Google Scholar
• 44. Kolanowski W.: Bioavailability of omega-3 PUFA from foodsenriched with fish oil. Pol. J. Food Nutr. Sci., 2005; 14/55: 335-340
  Google Scholar
• 45. Kolanowski W.: Długołańcuchowe wielonienasycone kwasytłuszczowe omega-3 – znaczenie zdrowotne w obniżaniu ryzykachorób cywilizacyjnych. Bromat. Chem. Toksykol., 2007; 3: 229-237
  Google Scholar
• 46. Kolanowski W., Uchman Z., Świderski F.: O szacowanie poziomudługołańcuchowych wielonienasyconych kwasów tłuszczowychw diecie dorosłych mieszkańców Warszawy. Bromat. Chem. Toksykol.,2004; 37: 137-144
  Google Scholar
• 47. Koletzko B., Beblo S., Demmelmair H., Müller-Felber W.,Hanebutt F.L.: Does dietary DHA improve neural function in children?Observations in phenylketonuria. Prostaglandins Leukot. Essent.Fatty Acids, 2009; 81: 159-164
  Google Scholar
• 48. Kornacewicz-Jach Z., Przybycień K.: Rola kwasów omega-3w optymalizacji standardowej farmakoterapii w prewencji wtórnejchoroby wieńcowej. Post. Kardiol. Interw., 2009; 5: 99-107
  Google Scholar
• 49. Kozłowska-Wojciechowska M.: Dieta a zespół metaboliczny. Jakitłuszcz i w jakiej ilości jest niezbędny w diecie pacjentów z zespołemmetabolicznym? Kardiol. Oparta na Faktach, 2010; 1: 29-32
  Google Scholar
• 50. Kremmyda L.S., Vlachava M., Noakes P.S., Diaper N.D., MilesE.A., Calder P.C.: Atopy risk in infants and children in relation toearly exposure to fish, oily fish, or long-chain omega-3 fatty acids:a systematic review. Clin. Rev. Allergy Immunol., 2011; 41: 36-66
  Google Scholar
• 51. Lok A., Assies J., Koeter M.W., Bockting C.L., Wouters L.F., MockingR.J., Schene A.H.: Sustained medically unexplained physicalsymptoms in euthymic patients with recurrent depression: predictivevalue for recurrence and associations with omega 3 – and
  Google Scholar
• 52. Łoś-Rychalska E., Czerwionka-Szaflarska M.: Długołańcuchowewielonienasycone kwasy tłuszczowe szeregu omega-3 w diecie kobietciężarnych, karmiących, niemowląt i małych dzieci. Gastroenterol.Pol., 2010; 17: 304-312
  Google Scholar
• 53. Ma T., Liaset B., Hao Q., Petersen R.K., Fjær E., Ngo H.T., LillefosseH.H., Ringholm S., Sonne S.B., Treebak J.T., Pilegaard H., FrøylandL., Kristiansen K., Madsen L.: Sucrose counteracts the anti-inflammatoryeffect of fish oil in adipose tissue and increases obesity developmentin mice. PLoS One, 2011; 6: e21647
  Google Scholar
• 54. MacLean C.H., Newberry S.J., Mojica W.A., Khanna P., Issa A.M.,Suttorp M.J., Lim Y.W., Traina S.B., Hilton L., Garland R., Morton S.C.:Effects of omega-3 fatty acids on cancer risk: a systematic review.JAMA, 2006; 295: 403-415
  Google Scholar
• 55. Maggio M., Artoni A., Lauretani F., Borghi L., Nouvenne A., ValentiG., Ceda G.P.: The impact of omega-3 fatty acids on osteoporosis.Curr. Pharm. Des, 2009; 15: 4157-4164
  Google Scholar
• 56. Marciniak-Łukasiak K.: Rola i znaczenie kwasów tluszczowychomega-3. Żywn. Nauka Technol. Jakość, 2011; 79, 24-35
  Google Scholar
• 57. Marugame T., Kamo K., Katanoda K., Ajiki W., Sobue T.: Cancerincidence and incidence rates in Japan in 2000: Estimates based ondata from 11 population-based cancer registries. Jpn. J. Clin. Oncol.,2006; 36: 668-675
  Google Scholar
• 58. Matias I., Di Marzo V.: Endocannabinoids and the control of energybalance. Trends Endocrinol. Metab., 2007; 18: 27-37
  Google Scholar
• 59. Mayser P., Grimm H., Grimminger F.: n-3 fatty acids in psoriasis.Br. J. Nutr., 2002; 87 (Suppl. 1): S77-S82
  Google Scholar
• 60. McManus A., Merga M., Newton W.: Omega-3 fatty acids. Whatconsumers need to know. Appetite, 2011; 57: 80-83
  Google Scholar
• 61. McNamara R.K., Strawn J.R.: Role of long-chain omega-3 fattyacids in psychiatric practice. PharmaNutrition, 2013; 1: 41-49
  Google Scholar
• 62. Mello A.H., Gassenferth A., Souza L.R., Fortunato J.J., Rezin G.T.:ω-3 and major depression: a review. Acta Neuropsychiatr., 2014;26: 178-85
  Google Scholar
• 63. Mińkowski K., Zawada K., Ptasznik S., Kalinowski A.: Wpływzwiązków fenolowych nasion na stabilność oksydacyjną i aktywnośćantyrodnikową wytłoczonych z nich olejów bogatych w PUFA n-3,Żywn. Nauka Technol. Jakość, 2013; 89: 118-132
  Google Scholar
• 64. Mori T.A., Beilin L.J., Burke V., Morris J., Ritchie J.: Interactionsbetween dietary fat, fish, and fish oils and their effects on plateletfunction in men at risk of cardiovascular disease. .Arterioscler.Thromb. Vasc. Biol., 1997; 17: 279-286
  Google Scholar
• 65. Mousa S.A.: Antithrombotic effects of naturally derived productson coagulation and platelet function. Methods Mol. Biol., 2010;663: 229-240
  Google Scholar
• 66. Mozaffarian D.: Fish and n-3 fatty acids for the prevention offatal coronary heart disease and sudden cardiac death. Am. J. Clin.Nutr., 2008; 87: 1991S-1996S
  Google Scholar
• 67. Mozaffarian D., Wu J.H.: Omega-3 fatty acids and cardiovasculardisease: effects on risk factors, molecular pathways, and clinicalevents. J. Am. Coll. Cardiol., 2011; 58: 2047-2067
  Google Scholar
• 68. Musacchio E., Priante G., Valvason C., Baggio B., Sartori L.: Eicosapentaenoicacid modulates CyA-induced proinflammatory cytokineover-expression in osteoblastic cells in vitro. J. Biol. Regul. Homeost.Agents, 2012; 26: 663-670
  Google Scholar
• 69. Naba H., Kakinuma C., Ohnishi S., Ogihara T.: Improving effectof ethyl eicosapentanoate on statin-induced rhabdomyolysisin Eisai hyperbilirubinemic rats. Biochem. Biophys. Res. Commun.,2006; 340: 215-220
  Google Scholar
• 70. Nakayama M., Fukuda N., Watanabe Y., Soma M., Hu W.Y., KishiokaH., Satoh C., Kubo A., Kanmatsuse K.: Low dose of eicosapentaenoicacid inhibits the exaggerated growth of vascular smooth musclecells from spontaneously hypertensive rats through suppression oftransforming growth factor-β. J. Hypertens., 1999; 17: 1421-1430
  Google Scholar
• 71. Necyk C., Ware M.A., Arnason J.T., Tsuyuki R.T., Boon H., Vohra S.:Increased bruising with the combination of long-chain omega-3 fattyacids, flaxseed oil and clopidogrel. Can. Pharm. J., 2013; 146: 93-96
  Google Scholar
• 72. Nemets B., Stahl Z., Belmaker R.H.: Addition of omega-3 fattyacid to maintenance medication treatment for recurrent unipolardepressive disorder. Am. J. Psychiatry, 2002; 159: 477-479
  Google Scholar
• 73. Nielsen N.S., Jacobsen C.: Methods for reducing lipid oxidationin fish-oil-enriched energy bars. Int. J. Food Sci. Technol., 2009; 44:1536-1546
  Google Scholar
• 74. Oh D.Y., Talukdar S., Bae E.J., Imamura T., Morinaga H., Fan W.,Li P., Lu W.J., Watkins S.M., Olefsky J.M.: GPR120 is an omega-3 fattyacid receptor mediating potent anti-inflammatory and insulin-sensitizingeffects. Cell, 2010; 142: 687-698
  Google Scholar
• 75. Oosthuizen W., Vorster H.H., Jerling J.C., Barnard H.C., SmutsC.M., Silvis N., Kruger A., Venter C.S.: Both fish oil and olive oil loweredplasma fibrinogen in women with high baseline fibrinogenlevels. Thromb. Haemost., 1994; 72: 557-562
  Google Scholar
• 76. Pacifico L., Giansanti S., Gallozzi A., Chiesa C.: Long chain omega-3polyunsaturated fatty acids in pediatric metabolic syndrome.Mini Rev. Med. Chem., 2014; 14: 791-804
  Google Scholar
• 77. Paniagua J.A., Pérez-Martinez P., Gjelstad I.M., Tierney A.C., Delgado-ListaJ., Defoort C., Blaak E.E., Risérus U., Drevon C.A., Kiec-WilkB., Lovegrove J.A., Roche H.M., López-Miranda J.: A low-fat high-carbohydratediet supplemented with long-chain n-3 PUFA reduces therisk of the metabolic syndrome. Atherosclerosis, 2011; 218: 443-450
  Google Scholar
• 78. Parker G., Hegarty B., Granville-Smith I., Ho J., Paterson A., GokiertA., Hadzi-Pavlovic D.: Is essential fatty acid status in late pregnancypredictive of post-natal depression? Acta Psychiatr. Scand.,2015; 131: 148-156
  Google Scholar
• 79. Parra D., Ramel A., Bandarra N., Kiely M., Martinez J.A., ThorsdottirI.: A diet rich in long chain omega-3 fatty acids modulatessatiety in overweight and obese volunteers during weight loss. Appetite,2008; 51: 676-680
  Google Scholar
• 80. Picone O., Marszalek A., Servely J.L., Chavatte-Palmer P.: Effectsof omega-3 supplementation in pregnant women. J. Gynecol. Obstet.Biol. Reprod., 2009; 38: 117-124
  Google Scholar
• 81. Poudyal H., Panchal S.K., Diwan V., Brown L.: Omega-3 fatty acidsand metabolic syndrome: effects and emerging mechanisms ofaction. Prog. Lipid Res., 2011; 50: 372–387
  Google Scholar
• 82. Putadechakum S., Tanphaichitr V., Leelahagul P., PakpeankitvatanaV., Surapisitchart T., Komindr S.: Long-term treatment of N-3PUFAS on plasma lipoprotein levels and fatty acid composition oftotal serum and erythrocyte lipids in hypertriglyceridemic patients.J. Med. Assoc. Thai., 2005; 88: 181-186
  Google Scholar
• 83. Qureshi N.A., Al-Bedah A.M.: Mood disorders and complementaryand alternative medicine: a literature review. Neuropsychiatr.Dis. Treat., 2013; 9: 639-658
  Google Scholar
• 84. Riemer S., Maes M., Christophe A., Rief W.: Lowered ω-3 PUFAsare related to major depression, but not to somatization syndrome.J. Affect. Disord., 2010, 123: 173-180
  Google Scholar
• 85. Rose D.P., Connolly J.M.: Omega-3 fatty acids as cancer chemopreventiveagents. Pharmacol. Ther., 1999; 83: 217-244
  Google Scholar
• 86. Roth E.M., Harris W.S.: Fish oil for primary and secondary preventionof coronary heart disease. Curr. Atheroscler. Rep., 2010;12: 66-72
  Google Scholar
• 87. Ruggiero C., Lattanzio F., Lauretani F., Gasperini B., AndresLacuevaC., Cherubini A.: Ω-3 polyunsaturated fatty acids and immune-mediateddiseases: inflammatory bowel disease and rheumatoidarthritis. Curr. Pharm. Des., 2009; 15: 4135-4148
  Google Scholar
• 88. Russell F.D., Bürgin-Maunder C.S.: Distinguishing health benefitsof eicosapentaenoic and docosahexaenoic acids. Mar. Drugs,2012; 10: 2535-2559
  Google Scholar
• 89. Ruzickova J., Rossmeisl M., Prazak T., Flachs P., Sponarova J.,Veck M., Tvrzicka E., Bryhn M., Kopecky J.: Omega-3 PUFA of marineorigin limit diet-induced obesity in mice by reducing cellularity ofadipose tissue. Lipids, 2004; 39: 1177-1185
  Google Scholar
• 90. Sallis H., Steer C., Paternoster L., Davey Smith G., Evans J.: Perinataldepression and omega-3 fatty acids: a Mendelian randomisationstudy. J. Affect. Disord., 2014; 166: 124-131
  Google Scholar
• 91. Saravanan P., Davidson N.C.: The role of omega-3 fatty acids inprimary prevention of coronary artery disease and in atrial fibrillationis controversial. J. Am. Coll. Cardiol., 2010; 55: 410-411
  Google Scholar
• 92. Schley P.D., Jijon H.B., Robinson L.E., Field C.J.: Mechanisms ofomega-3 fatty acid-induced growth inhibition in MDA-MB-231 humanbreast cancer cells. Breast Cancer Res. Treat., 2005; 92: 187-195
  Google Scholar
• 93. Schram L.B., Nielsen C.J., Porsgaard T., Nielsen N.S., Holm R.,Mu H.: Food matrices affect the bioavailability of (n – 3) polyunsaturatedfatty acids in a single meal study in humans. Food Res.Internat., 2007; 40: 1062-1068
  Google Scholar
• 94. Simopoulos A.P.: The importance of the omega-6/omega-3 fattyacid ratio in cardiovascular disease and other chronic diseases. Exp.Biol. Med., 2008; 233: 674-688
  Google Scholar
• 95. Tatoń J., Czech A., Bernas M.: Otyłość. Zespół metaboliczny.,Wydawnictwo Lekarskie PZWL, Warszawa 2007
  Google Scholar
• 96. Tavazzi L., Maggioni A.P., Marchioli R., Barlera S., Franzosi M.G.,Latini R., Lucci D., Nicolosi G.L., Porcu M., Tognoni G.: Effect of n-3polyunsaturated fatty acids in patients with chronic heart failure(the GISSI-HF trial): a randomised, double-blind, placebo-controlledtrial. Lancet, 2008; 372: 1223-1230
  Google Scholar
• 97. Thorsdottir I., Tomasson H., Gunnarsdottir I., Gisladottir E., KielyM., Parra M.D., Bandarra N.M., Schaafsma G., Martinéz J.A.: Randomizedtrial of weight-loss-diets for young adults varying in fish andfish oil content. Int. J. Obes., 2007; 31: 1560-1566
  Google Scholar
• 98. Thorseng T., Witte D.R., Vistisen D., Borch-Johnsen K., BjerregaardP., Jorgensen M.E.: The association betwen n-3 fatty acidsin erythrocyte membranes and insulin resistance: the Inuit Healthin Transition Study. Int. J. Circumpolar Health, 2009; 68: 327-336
  Google Scholar
• 99. Trombetta A., Maggiora M., Martinasso G., Cotogni P., CanutoR.A., Muzio G., Arachidonic and docosahexaenoic acids reduce thegrowth of A549 human lung-tumor cells increasing lipid peroxidationand PPARs. Chem. Biol. Interact, 2007; 165: 239-250
  Google Scholar
• 100. Wall R., Ross R.P., Fitzgerald G.F., Stanton C.: Fatty acids fromfish: the anti-inflammatory potential of long-chain omega-3 fattyacids. Nutr. Rev., 2010; 68: 280-289
  Google Scholar
• 101. Wąsowicz E., Gramza A., Hęś M., Jeleń H.H., Korczak J., MałeckaM., Mildner-Szkudlarz S., Rudzińska M., Samotyja U., ZawirskaWojtasiakR.: Oxidation of lipids in food. Pol. J. Food Nutr. Sci., 2004;13: 87-100
  Google Scholar
• 102. Wcisło T., Rogowski W.: Rola wielonienasyconych kwasów tłuszczowychomega-3 w organizmie człowieka. Cardiovasc. Forum, 2006;11: 39-43
  Google Scholar
• 103. Witte K.K., Clark A.L.: Wielonienasycone kwasy tłuszczowez ryb morskich w leczeniu niewydolności serca. Czy dane klinicznepotwierdzają teoretyczne korzyści? Pol. Arch. Med. Wewn., 2009;119: 162-169
  Google Scholar
• 104. Yoshida R., Ohkuri T., Jyotaki M., Yasuo T., Horio N., YasumatsuK., Sanematsu K., Shigemura N., Yamamoto T., Margolskee R.F., NinomiyaY.: Endocannabinoids selectively enhance sweet taste. Proc.Natl. Acad. Sci. USA, 2010; 107: 935-939
  Google Scholar
• 105. Zabłocka K., Biernat J.: Wpływ wybranych składników pożywieniana ryzyko rozwoju raka płuca – nienasycone kwasy tłuszczowe,izotiocyjaniany, selen. Współcz. Onkol., 2010; 14: 54-58
  Google Scholar
• 106. Zawadzki M., Szechiński J., Kowalczyk A., Kozłowski D.: Skutecznośćekstraktu lipidowego Perna canalicus w leczeniu chorób układuruchu w starszym wieku. Geriatria, 2010; 4: 21-25
  Google Scholar
• 107. Zespół Ekspertów Polskiego Towarzystwa Ginekologicznego:Rekomendacje Zespołu Ekspertów Polskiego Towarzystwa Ginekologicznegow zakresie stosowania kwasów omega-3 w położnictwie.Ginekol. Pol., 2010; 81: 467-469
  Google Scholar
• 108. Zhu M.W., Tang D.N., Hou J., Wei J.M., Hua B., Sun J.H., CuiH.Y.: Impact of fish oil enriched total parenteral nutrition on elderlypatients after colorectal cancer surgery. Chin. Med. J., 2012;125: 178-181
  Google Scholar

Full text